A Phase 1 interventional study of VX-147 in Focal Segmental Glomerulosclerosis (FSGS), sponsored by Vertex Pharmaceuticals Incorporated. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-13.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States — 18 open to participants now, 21 under way, 2 of them phase 3. Glomerulosclerosis, Focal Segmental · United States.
Among the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, this one is the 32nd largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2023, is one of 8 in phase 1, and was the 60th registered.
106 studies on the registry are indexed under Glomerulosclerosis, Focal Segmental; 34 are open to participants now.
Browse Glomerulosclerosis, Focal Segmental studies →18 of the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States are open now. Recruiting first, the newest first:
National Human Genome Research Institute (NHGRI) · Sites in United States
Ages 18–115
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 34 more countries
Ages 12+
Akebia Therapeutics · Sites in United States
Ages 18+
Meyer Children's Hospital IRCCS · Sites in United States, Germany, Italy and 2 more countries
Ages 0–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Glomerulosclerosis, Focal Segmental studies recruiting now, 11 (35%) set no upper age limit and 13 (42%) stop at 75 or younger; 23 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 31 · Phase 3 5 · Phase 4 4
First in 1996; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 30 across 73 interventional studies indexed under Glomerulosclerosis, Focal Segmental.
Median enrollment 30 across the 56 interventional studies, 252 across the 13 observational. Of the 45 that completed or were terminated, 23 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 69 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
Vertex Pharmaceuticals Incorporated has 3 studies filed under Glomerulosclerosis, Focal Segmental — fewer than ten, so there is no comparison to draw.
10 of the studies in Glomerulosclerosis, Focal Segmental with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01094327University of MiamiProteinuria in Pre and Post Transplant | 2026-11-30 |
| NCT06500702SanofiA Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease | 2026-12-23 |
| NCT07219121Travere Therapeutics, Inc.Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis | 2027-03 |
| NCT05583942Northwell HealthA Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) | 2027-03-01 |
| NCT05588063Northwell HealthtaVNS for FRNS in Children | 2027-03-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the relative bioavailability (BA) and the effect of food on the pharmacokinetics (PK), and the safety and tolerability of VX-147 test tablet formulation.
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive VX-147 reference tablet under fasted condition in Treatment Period 1, then VX-147 test tablet under fed condition in Treatment Period 2, and VX-147 test tablet under fasted condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.
Drug: VX-147
Participants will receive VX-147 test tablet under fed condition in Treatment Period 1, then VX-147 test tablet under fasted condition in Treatment Period 2, and VX-147 reference tablet under fasted condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.
Drug: VX-147
Participants will receive VX-147 test tablet under fasted condition in Treatment Period 1, then VX-147 reference tablet under fasted condition in Treatment Period 2, and VX-147 test tablet under fed condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.
Drug: VX-147
Tablets for oral administration.
Maximum Observed Plasma Concentration (Cmax) of VX-147 Test Compared to VX-147 Reference
Time frame: From Day 1 up to Day 16
Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-147 Test Compared to VX-147 Reference
Time frame: From Day 1 up to Day 16
Cmax of VX-147 Test Compared Under Fed Versus Fasted State
Time frame: From Day 1 up to Day 16
AUC(0-inf) of VX-147 Test Compared Under Fed Versus Fasted State
Time frame: From Day 1 up to Day 16
Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious AEs
Time frame: From Day -1 up to Day 27
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing.
No publications or documents are linked to this record.
Ran from Jul 2023 to primary completion in Sep 2023, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inaxaplin
Glomerulosclerosis, Focal Segmental →
Vertex Pharmaceuticals Incorporated →